AGCT GmbH

Liquid biopsy cancer testing Non-invasive liquid biopsy tests are aimed at changing cancer diagnostics and treatment. Existing technologies have performance limitations and narrow the potentials of liquid biopsy. What we do AGCT developed a PCR-based assay technology that introduces an exceptional limit of detection for liquid biopsy cancer testing. At the same time the technology can be applied on standard laboratory equipment. AGCT’s technology AGCT’s cyberPCR technology creates a new kind of sensitivity and specificity in cancer detection. The proprietary technology already discriminates at the amplification step. Only mutant target sequences are amplified, permitting an unprecedented signal-noise ratio and a revolutionary level of rare mutant molecule detection for liquid biopsy.